Form 8-K LogicBio Therapeutics, For: Jun 11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2021

 

LOGICBIO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-38707		47-1514975
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

65 Hayden Avenue, 2nd Floor Lexington, MA		02421
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 245-0399

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LOGC		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

LogicBio Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 11, 2021. The stockholders (i) elected three Class III directors to the Company’s Board of Directors (the “Board”) to serve until the 2024 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal; and (ii) ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

(i) The Class III directors elected to the Board, as well as the number of votes for, votes withheld, abstentions and broker non-votes with respect to each of these individuals, are set forth below:

 

Director		Votes For				Votes Against				Abstentions				Broker Non-Votes
Frederic Chereau			19,026,582				698,869				48,302				8,088,772
Richard Moscicki, M.D.			18,843,241				881,883				48,629				8,088,772
Michael Wyzga			14,894,263				4,830,504				48,986				8,088,772

(ii) The proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 received the following votes:

 

Votes For:			27,773,669
Votes Against:			34,218
Abstentions:			54,638
Broker Non-Votes:			—

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 15, 2021						LOGICBIO THERAPEUTICS, INC.
						By: /s/ Cecilia Jones
						Name: Cecilia Jones
						Title: Chief Financial Officer